6505--Bevacizumab Injection

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Bevacizumab injection pharmaceutical products to be supplied through pharmaceutical prime vendors (PPVs) to VA facilities, Department of Defense, Indian Health Service, and Bureau of Prisons. The solicitation seeks multiple strengths of Bevacizumab (25mg/mL in 4mL and 16mL vials), including brand names such as Avastin, Mvasi, Alymsys, Vegzelma, and Zirabev. The contract will be awarded as a firm-fixed price requirements contract with a one-year base period and four one-year option periods. Evaluation will be conducted using a lowest price technically acceptable (LPTA) methodology, with offerors required to meet all technical specifications and FDA cGMP compliance standards. Proposals are due on March 6, 2025, at 2:30 PM CT, with a mandatory 60-day implementation period for establishing distribution agreements with prime vendors.

The solicitation is unrestricted, meaning all businesses can compete, though large businesses must submit a subcontracting plan for contracts exceeding $750,000. Estimated annual quantities include 23,448 vials for the 4mL size and 13,841 vials for the 16mL size. Contractors must distribute products through McKesson Corporation (VA PPV) and specified DoD PPV contractors, and include a 0.5% Cost Recovery Fee in their pricing. Offerors must provide unique 11-digit NDC numbers specific to their company. The contract will leverage the Pharmaceutical Preparation Manufacturing NAICS code (325412) and the Drugs and Biologicals PSC category (6505). While no specific incumbent is mentioned, the solicitation indicates a structured approach to pharmaceutical product procurement across multiple federal healthcare systems.